A BILL 
To amend title IX of the Public Health Service Act to 
revise the operations of the United States Preventive 
Services Task Force, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘USPSTF Trans-
4
parency and Accountability Act of 2019’’. 
5
02:37 Jul 09, 2019
H3534
2 
•HR 3534 IH
SEC. 2. CHANGES TO UNITED STATES PREVENTIVE SERV-
1
ICES TASK FORCE. 
2
(a) IN GENERAL.—Subsection (a) of section 915 of 
3
the Public Health Service Act (42 U.S.C. 299b–4) is 
4
amended— 
5
(1) by amending the heading to read as follows: 
6
‘‘UNITED
STATES
PREVENTIVE
SERVICES
TASK 
7
FORCE’’; 
8
(2) by amending paragraph (1) to read as fol-
9
lows: 
10
‘‘(1) ESTABLISHMENT AND PURPOSE.—The Di-
11
rector may establish and periodically convene the 
12
United States Preventive Services Task Force (in 
13
this section referred to as the ‘Task Force’). The 
14
Task Force shall review the scientific evidence and 
15
new science related to the effectiveness and appro-
16
priateness of clinical preventive services for the pur-
17
pose of developing recommendations for primary 
18
care clinicians and the health care community and 
19
updating previous clinical preventive recommenda-
20
tions.’’; 
21
(3) by striking paragraph (3); 
22
(4) by redesignating paragraphs (4) through 
23
(7) as paragraphs (9) through (12), respectively; 
24
(5) by inserting after paragraph (2) the fol-
25
lowing new paragraphs: 
26
02:37 Jul 09, 2019
H3534
3 
•HR 3534 IH
‘‘(3) COMPOSITION.— 
1
‘‘(A) IN GENERAL.—The Task Force shall 
2
be composed of individuals that collectively have 
3
appropriate scientific expertise, including in 
4
fields of health sciences research, health eco-
5
nomics, health promotion, disease prevention, 
6
and clinical care. The Task Force shall include 
7
a balanced representation of practicing primary 
8
and specialty care providers (including in the 
9
fields of health services research, health eco-
10
nomics, and clinical care), patients, and health 
11
care consumers. 
12
‘‘(B) NOTICE.—Before appointing mem-
13
bers to the Task Force, the Director shall pro-
14
vide notice in the Federal Register to give per-
15
sons an opportunity to nominate potential mem-
16
bers. 
17
‘‘(4) REVIEW AND CONSULTATION.— 
18
‘‘(A) RESEARCH PLANS.— 
19
‘‘(i) IN GENERAL.—In conducting its 
20
reviews under paragraph (1), the Task 
21
Force shall publish one or more proposed 
22
research plans (in this subsection referred 
23
to as a ‘research plan’) to guide the Task 
24
Force’s systematic review of the evidence 
25
02:37 Jul 09, 2019
H3534
4 
•HR 3534 IH
referred to in such paragraph. Each such 
1
plan shall include an analytic framework, 
2
key questions, and a literature search 
3
strategy or research approach, and shall 
4
incorporate the methodological guidelines 
5
developed under clause (iii). 
6
‘‘(ii) PUBLICATION; PUBLIC COMMENT 
7
PERIOD.—The Task Force shall provide 
8
for the publication in the Federal Register 
9
of a request for public comments on each 
10
research plan and shall accept comments 
11
on such plan during a period of not less 
12
than 45 days. The Director shall make 
13
publicly available comments submitted in 
14
response to a request for public comments. 
15
Any final research plan shall be made 
16
available to the public and include a dis-
17
cussion of the comments received with re-
18
spect to such plan and responses to such 
19
comments. The Task Force, with the con-
20
currence of the Director, may change such 
21
a research plan through the same process 
22
as applied to the initial adoption of such 
23
plan. 
24
02:37 Jul 09, 2019
H3534
5 
•HR 3534 IH
‘‘(iii) CRITERIA.—The Director shall 
1
design and regularly update guidelines for 
2
proper methodological standards for incor-
3
poration into such research plans. Such 
4
guidelines shall include measures for ap-
5
propriate validity, for risk adjustment, for 
6
timeliness, for input from relevant experts 
7
and peers in the respective communities, 
8
for accounting for all relevant subpopula-
9
tions (including disparities by gender, race, 
10
ethnicity, socioeconomic status, and geo-
11
graphic location), and for other health out-
12
come measurements. Such guidelines and 
13
methodological standards shall ensure the 
14
consideration of any evidence concerning 
15
any relevant subpopulations (including dis-
16
parities by gender, race, ethnicity, genetic 
17
predisposition, socioeconomic status, and 
18
geographic location), any real world evi-
19
dence, any recent evidence, and any United 
20
States-based studies. 
21
‘‘(iv) CONSULTATION
ON
RESEARCH 
22
PLANS.—The Director shall facilitate co-
23
ordination and interaction with other agen-
24
cies and departments in the preparation 
25
02:37 Jul 09, 2019
H3534
6 
•HR 3534 IH
and publication of research plans (taking 
1
into consideration research and findings by 
2
other agencies and departments) and 
3
methodological standards under clause 
4
(iii), including with the National Institutes 
5
of Health, the National Cancer Institute, 
6
the National Institute on Minority Health 
7
and Health Disparities, the Centers for 
8
Disease Control and Prevention, the De-
9
partment of Defense, the Department of 
10
Veterans Affairs, the Centers for Medicare 
11
& Medicaid Services, and the Patient-Cen-
12
tered Outcomes Research Institute. 
13
‘‘(B) EVIDENCE REPORTS.— 
14
‘‘(i) INITIAL PUBLICATION.—The Di-
15
rector shall make publicly available each 
16
systematic evidence review and any related 
17
reports that serve as the foundation for 
18
any recommendation of the Task Force 
19
and publish in the Federal Register a re-
20
quest for public comments on such review 
21
or related reports. 
22
‘‘(ii) PUBLIC COMMENT PERIOD.—The 
23
Director shall accept comments on any 
24
draft evidence report published under 
25
02:37 Jul 09, 2019
H3534
7 
•HR 3534 IH
clause (i) during a period of at least 45 
1
days. The Director shall make publicly 
2
available comments submitted in response 
3
to a request for public comment. Each 
4
final evidence review shall include a de-
5
scription of comments submitted on the 
6
draft evidence review and the response of 
7
the Task Force to such comments. 
8
‘‘(iii) REVIEW
BY
EXTERNAL
EX-
9
PERTS.—No such evidence report shall be 
10
published prior to it being reviewed by a 
11
panel of external subject matter experts 
12
that includes provider and patient rep-
13
resentatives. Each such report shall in-
14
clude a description of the panel that con-
15
ducted such review. Such description shall 
16
include information on each panel member, 
17
including name, academic degree (or de-
18
grees), affiliations, and related expertise. 
19
‘‘(C) RECOMMENDATION STATEMENTS.— 
20
‘‘(i) PUBLICATION
OF
DRAFT
REC-
21
OMMENDATIONS.—The Director shall make 
22
publicly available each draft recommenda-
23
tion statement (as that term is used for 
24
purposes of section 7 of the U.S. Preven-
25
02:37 Jul 09, 2019
H3534
8 
•HR 3534 IH
tive Services Task Force Procedure Man-
1
ual, as in effect on April 1, 2019) and 
2
shall provide for the publication in the 
3
Federal Register of a request for com-
4
ments and accept comments during a pe-
5
riod of not less than 45 days. 
6
‘‘(ii) 
CONSULTATION
ON
REC-
7
OMMENDATIONS.—Before voting on a draft 
8
or final recommendation statement (as 
9
that term is used for purposes of section 7 
10
of the procedure manual referred to in 
11
clause (i)), the Task Force shall— 
12
‘‘(I) consult with relevant stake-
13
holders, including provider groups, 
14
practicing specialists that treat the 
15
specific disease under review, and rel-
16
evant patient and disease advocacy or-
17
ganizations; and 
18
‘‘(II) take into account the feed-
19
back provided by the board. 
20
‘‘(iii) PUBLIC AVAILABILITY OF COM-
21
MENTS AND INCLUSION OF DESCRIPTION 
22
OF
COMMENTS
IN
FINAL
STATEMENT.— 
23
The Director shall make comments re-
24
ceived pursuant to clause (i) publicly avail-
25
02:37 Jul 09, 2019
H3534
9 
•HR 3534 IH
able. Any final recommendation statement 
1
shall include a description of comments re-
2
ceived on the draft recommendation state-
3
ment and recommendations of other Fed-
4
eral agencies or organizations relating to 
5
the topic of the statement. The Director 
6
shall make final recommendation state-
7
ments publicly available, including through 
8
publication in the Federal Register. 
9
‘‘(iv) CONSIDERATION.—In publishing 
10
draft or final recommendation statements 
11
(as those terms are used for purposes of 
12
section 7 of the procedure manual referred 
13
to in clause (i)), the Task Force shall con-
14
sider— 
15
‘‘(I) the impact of its rec-
16
ommendations on the health care 
17
community; 
18
‘‘(II) whether a preventive service 
19
is beneficial for some individuals and 
20
the need to encourage a discussion of 
21
benefits and risks for those individ-
22
uals; and 
23
‘‘(III) how its specific assignment 
24
of a grade to a product or service may 
25
02:37 Jul 09, 2019
H3534
10 
•HR 3534 IH
affect coverage and access to such 
1
product or service under Federal pro-
2
grams and private health insurance 
3
coverage. 
4
‘‘(v) DISSEMINATION
OF
EVIDENCE- 
5
BASED
RECOMMENDATIONS.—The 
Task 
6
Force shall publish and disseminate the 
7
evidence-based recommendations after con-
8
sultation with the following: 
9
‘‘(I) Relevant patient organiza-
10
tions. 
11
‘‘(II) Providers of clinical serv-
12
ices, including community-based pro-
13
viders and specialty physicians. 
14
‘‘(III) The Department of Vet-
15
erans Affairs, the Centers for Medi-
16
care & Medicaid Services, and the 
17
Centers for Disease Control and Pre-
18
vention. 
19
‘‘(D) GRADING SYSTEM.—Subject to sub-
20
paragraph (E), in publishing recommendation 
21
statements (as that term is used for purposes 
22
of section 7 of the procedure manual referred to 
23
in clause (i)), the Task Force shall grade prod-
24
ucts and services consistent with the following: 
25
02:37 Jul 09, 2019
H3534
11 
•HR 3534 IH
‘‘(i) GRADE A.—The Task Force shall 
1
assign a product or service Grade A if the 
2
Task Force concludes that the current evi-
3
dence is sufficient to assess the balance of 
4
benefits and risks of the product or service, 
5
and, on the basis of such evidence, rec-
6
ommends the product or service and deter-
7
mines that there is high certainty that the 
8
net benefit from the product or service is 
9
substantial. 
10
‘‘(ii) GRADE
B.—The Task Force 
11
shall assign a product or service Grade B 
12
if the Task Force concludes that the cur-
13
rent evidence is sufficient to assess the bal-
14
ance of benefits and risks of the product or 
15
service, and, on the basis of such evidence, 
16
recommends the product or service and de-
17
termines that there is high certainty that 
18
the net benefit of the product or service is 
19
moderate or there is moderate certainty 
20
that the net benefit of the product or serv-
21
ice is moderate to substantial. 
22
‘‘(iii) GRADE
C.—The Task Force 
23
shall assign a product or service Grade C 
24
if the Task Force concludes that— 
25
02:37 Jul 09, 2019
H3534
12 
•HR 3534 IH
‘‘(I) the current evidence is suffi-
1
cient to assess the balance of benefits 
2
and risks of the product or service; 
3
‘‘(II) on the basis of such evi-
4
dence, does not make a recommenda-
5
tion of the product or service and cli-
6
nicians may provide this product or 
7
service to selected patients depending 
8
on individual circumstances; and 
9
‘‘(III) for most individuals with-
10
out signs or symptoms of a particular 
11
disease or condition there is at least 
12
moderate certainty that the net ben-
13
efit is small. 
14
‘‘(iv) GRADE
D.—The Task Force 
15
shall assign a product or service Grade D 
16
if the Task Force concludes that the cur-
17
rent evidence is sufficient to assess the bal-
18
ance of benefits and risks of the product or 
19
service, and, on the basis of such evidence, 
20
recommends against the product or service 
21
and determines that there is moderate or 
22
high certainty that the product or service 
23
has no net benefit or that the harm of the 
24
product or service outweighs the benefits. 
25
02:37 Jul 09, 2019
H3534
13 
•HR 3534 IH
‘‘(v) GRADE I.—The Task Force shall 
1
assign a product or service Grade I if the 
2
Task Force concludes that the current evi-
3
dence is not sufficient to assess the bal-
4
ance of benefits and risks of the product or 
5
service. 
6
‘‘(E) CHANGES IN GRADING SYSTEM.— 
7
‘‘(i) IN GENERAL.—The Director may 
8
provide, by regulation, for changes in the 
9
grading system described in subparagraph 
10
(D). 
11
‘‘(ii) IMPACT
OF
CHANGES.—If the 
12
Director makes a change in the grading 
13
system under clause (i) for a particular 
14
grade, the Task Force shall review and re- 
15
grade the products or services previously 
16
classified within that grade. Any such re-
17
view and regrading may be done through 
18
an expedited process so long as any change 
19
in grade does not take effect before the re-
20
view of that change in grade is completed. 
21
‘‘(5) ROLE OF AGENCY.—The Agency shall pro-
22
vide ongoing administrative, research, and technical 
23
support for the operations of the Task Force, includ-
24
ing coordinating and supporting the dissemination of 
25
02:37 Jul 09, 2019
H3534
14 
•HR 3534 IH
its recommendation statements, ensuring adequate 
1
staff resources, and assistance to those organizations 
2
requesting it for implementation of the recommenda-
3
tions of the Task Force. 
4
‘‘(6) 
PREVENTIVE
SERVICES
ADVISORY 
5
BOARD.— 
6
‘‘(A) IN GENERAL.—The Task Force shall 
7
convene a preventive services advisory board (in 
8
this subsection referred to as the ‘board’) com-
9
posed of representatives of appropriate public 
10
and private entities with an interest in clinical 
11
preventive services to advise the Task Force 
12
throughout the development of evidence-based 
13
recommendations on the use of clinical preven-
14
tive services. 
15
‘‘(B) MEMBERSHIP.—The members of the 
16
board shall include representatives of the fol-
17
lowing: 
18
‘‘(i) Patient groups. 
19
‘‘(ii) Providers of clinical services, in-
20
cluding community-based providers and 
21
specialty physicians. 
22
‘‘(iii) Federal departments and agen-
23
cies that have expertise in the clinical pre-
24
ventive service being reviewed. 
25
02:37 Jul 09, 2019
H3534
15 
•HR 3534 IH
‘‘(C) 
RESPONSIBILITIES.—The 
board 
1
shall— 
2
‘‘(i) recommend clinical preventive 
3
services for review by the Task Force; 
4
‘‘(ii) suggest scientific evidence for 
5
consideration by the Task Force related to 
6
reviews undertaken by the Task Force; 
7
‘‘(iii) provide feedback regarding the 
8
research plan, the evidence report, and 
9
draft recommendations by the Task Force; 
10
and 
11
‘‘(iv) assist with efforts regarding dis-
12
semination of recommendations by the Di-
13
rector. 
14
‘‘(D) MEETINGS.—The board shall meet as 
15
the chair of the board determines to be appro-
16
priate to fulfill the responsibilities described in 
17
paragraph (C), but not fewer than 2 times each 
18
year. 
19
‘‘(7) DISCLOSURE AND CONFLICTS OF INTER-
20
EST.—Prior to participating in a meeting of the 
21
Task Force or board, each member of the Task 
22
Force or board, respectively, shall disclose to the Di-
23
rector any potential, relevant financial interests in 
24
the same manner and to the same extent as an em-
25
02:37 Jul 09, 2019
H3534
16 
•HR 3534 IH
ployee of the executive branch of the United States, 
1
if the employee were participating in such meeting, 
2
would be required to disclose such interests under 
3
section 208 of title 18, United States Code. 
4
‘‘(8) NO
PAY; 
RECEIPT
OF
TRAVEL
EX-
5
PENSES.—Members of the Task Force or the board 
6
shall not receive any pay for service on the Task 
7
Force or board, but may receive travel expenses, in-
8
cluding a per diem, in accordance with applicable 
9
provisions of subchapter I of chapter 57 of title 5, 
10
United States Code.’’; and 
11
(6) by amending paragraph (10), as redesig-
12
nated by paragraph (4), to read as follows: 
13
‘‘(10) APPLICATION
OF
FACA.—The Federal 
14
Advisory Committee Act (5 U.S.C. App.) shall apply 
15
to the Task Force except that section 14 of such Act 
16
(relating to termination of advisory committees) 
17
shall not apply to the Task Force.’’. 
18
(b) EFFECTIVE DATE; TRANSITION.— 
19
(1) IN GENERAL.—The United States Preven-
20
tive Services Task Force shall not publish any draft 
21
or final recommendations on or after such date ex-
22
cept in accordance with such amendments. 
23
(2) RECONSTITUTION
OF
TASK
FORCE.—Not 
24
later than 180 days after the date of the enactment 
25
02:37 Jul 09, 2019
H3534
17 
•HR 3534 IH
of this Act, the Director of the Agency for 
1
Healthcare Research and Quality shall take steps to 
2
reconstitute the membership of the Task Force con-
3
sistent with section 915(a)(3) of the Public Health 
4
Service Act, as amended by subsection (a). 
5
(3) PREVIOUSLY
PUBLISHED
RECOMMENDA-
6
TIONS.—With respect to recommendations or guide-
7
lines published by such Task Force before the date 
8
of the enactment of this Act, under procedures es-
9
tablished by the Director of the Agency for 
10
Healthcare Research and Quality, the reconstituted 
11
Task Force shall undertake a review process con-
12
sistent with the following: 
13
(A) An organization may request the Task 
14
Force to review any such previous recommenda-
15
tion or guideline if such organization has addi-
16
tional peer-reviewed scientific evidence that pro-
17
vides new information relevant to the previous 
18
recommendation or guideline. 
19
(B) Based upon such requests, the Task 
20
Force shall establish a process for the review of 
21
previous recommendations or guidelines. 
22
(C) Such process shall include public no-
23
tice through the Federal Register and oppor-
24
tunity for comment and a determination to con-
25
02:37 Jul 09, 2019
H3534
18 
•HR 3534 IH
firm or modify such recommendations or guide-
1
lines. 
2
(D) The process shall, to the extent fea-
3
sible, be consistent with the procedures applied 
4
under the amendments made by subsection (a) 
5
for the promulgation of new recommendations. 
6
(c) ELIMINATION OF SECRETARIAL DISCRETION TO 
7
REMOVE CERTAIN PREVENTIVE SERVICES UNDER THE 
8
MEDICARE PROGRAM.—Section 1834(n) of the Social Se-
9
curity Act (42 U.S.C. 1395m(n)) is amended— 
10
(1) by striking paragraph (2); 
11
(2) by striking ‘‘; and’’ at the end of paragraph 
12
(1)(B) and inserting a period; 
13
(3) by redesignating subparagraphs (A) and 
14
(B) of paragraph (1) as paragraphs (1) and (2), re-
15
spectively, and moving their margins 2 ems to the 
16
left; and 
17
(4) by striking ‘‘may’’ and all that follows 
18
through ‘‘modify’’ and inserting ‘‘may modify’’. 
19
(d) APPLICATION TO SECRETARIAL DISCRETION TO 
20
REMOVE CERTAIN PREVENTIVE SERVICES UNDER THE 
21
MEDICARE PROGRAM.—Section 1834(n) of the Social Se-
22
curity Act (42 U.S.C. 1395m(n)), as amended by sub-
23
section (c), is further amended by adding at the end the 
24
following flush sentence: ‘‘Effective on the date of enact-
25
02:37 Jul 09, 2019
H3534
19 
•HR 3534 IH
ment of the USPSTF Transparency and Accountability 
1
Act of 2019, the Secretary may use the authority under 
2
this subsection only to modify coverage of a preventive 
3
service based on the recommendation or grade of the 
4
United States Preventive Services Task Force with respect 
5
to the service if such recommendation or grade was devel-
6
oped or updated in accordance with the amendments made 
7
by section 2(a) of such Act and if the Secretary has con-
8
curred with such recommendation or grade after consulta-
9
tion with other Federal health agencies and relevant pa-
10
tient and provider groups.’’. 
11
(e) APPLICATION TO PHYSICIAN QUALITY MEASURES 
12
UNDER THE MEDICARE PROGRAM.—Section 1848 of the 
13
Social Security Act (42 U.S.C. 1395w–4) is amended by 
14
adding at the end the following new subsection: 
15
‘‘(t) MEASURES
RELATED
TO
USPSTF REC-
16
OMMENDATIONS.—Effective on the date of enactment of 
17
the USPSTF Transparency and Accountability Act of 
18
2019, notwithstanding any other provision of this title, a 
19
quality measure related to a recommendation of the 
20
United States Preventive Services Task Force may be ap-
21
plied under this section only if such recommendation was 
22
developed or updated in accordance with the amendments 
23
made by section 2(a) of such Act and if the Secretary has 
24
concurred with such recommendation or grade after con-
25
02:37 Jul 09, 2019
H3534
20 
•HR 3534 IH
sultation with other Federal health agencies and relevant 
1
patient and provider groups.’’. 
2
Æ 
02:37 Jul 09, 2019
H3534
